Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMS) Finished Goods (2016 - 2024)

Historic Finished Goods for Fresenius Medical Care AG (FMS) over the last 16 years, with Q4 2024 value amounting to $1.3 billion.

  • Fresenius Medical Care AG's Finished Goods fell 476.49% to $1.3 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 billion, marking a year-over-year decrease of 476.49%. This contributed to the annual value of $1.3 billion for FY2024, which is 476.49% down from last year.
  • Fresenius Medical Care AG's Finished Goods amounted to $1.3 billion in Q4 2024, which was down 476.49% from $1.3 billion recorded in Q4 2023.
  • Fresenius Medical Care AG's Finished Goods' 5-year high stood at $1.4 billion during Q4 2021, with a 5-year trough of $1.3 billion in Q4 2024.
  • Its 5-year average for Finished Goods is $1.3 billion, with a median of $1.3 billion in 2023.
  • Its Finished Goods has fluctuated over the past 5 years, first surged by 2465.67% in 2020, then plummeted by 518.89% in 2022.
  • Over the past 5 years, Fresenius Medical Care AG's Finished Goods (Quarter) stood at $1.3 billion in 2020, then grew by 8.72% to $1.4 billion in 2021, then fell by 5.19% to $1.3 billion in 2022, then fell by 0.84% to $1.3 billion in 2023, then fell by 4.76% to $1.3 billion in 2024.
  • Its Finished Goods stands at $1.3 billion for Q4 2024, versus $1.3 billion for Q4 2023 and $1.3 billion for Q4 2022.